Elsevier

The Lancet

Volume 357, Issue 9261, 31 March 2001, Pages 973-974
The Lancet

Commentary
Antibiotics for preterm prelabour rupture of membranes and preterm labour?

https://doi.org/10.1016/S0140-6736(00)04253-7Get rights and content

References (3)

There are more references available in the full text version of this article.

Cited by (15)

  • No. 233-Antibiotic Therapy in Preterm Premature Rupture of the Membranes

    2017, Journal of Obstetrics and Gynaecology Canada
    Citation Excerpt :

    The authors concluded that erythromycin has a range of neonatal health benefits when administered to women with PPROM, but that co-amoxiclav should not be used because of its association with NEC.11 The study has been criticized because there were no differences in the composite primary outcome for any of the treatment groups when compared with placebo. 12 However, there were many significant differences in subgroup analyses (presented above).

  • Antibiotic therapy in preterm premature rupture of the membranes

    2009, Journal of Obstetrics and Gynaecology Canada
  • Antibiotic Therapy in Preterm Premature Rupture of the Membranes

    2009, Journal of Obstetrics and Gynaecology Canada
View all citing articles on Scopus
View full text